Comparing Assay Performance of  ELISA and Chemiluminescence  Immunoassay in Detecting Antibodies  to Hepatitis B Surface Antigen

Madiyal, Mridula

doi:10.7860/jcdr/2016/24108.8921

Cited by 20 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data also demonstrate noticeable differences of serum titers between ELISA and the CLIA assays used. These findings are in line with other studies on ELISA and CLIA assays showing that these assays have discrepancies in quantitative measurement but sound overall analytical agreement [10][11][12]. Moreover, recent data also suggest that even titers of different quantitative ELISA assays cannot be compared without further consideration [13,14].…”

Section: Discussionsupporting

confidence: 89%

Quantitative serological antibody testing for suspected neuroborreliosis

et al. 2020

View full text Add to dashboard Cite

Objective To assess the importance of serum IgG/IgM antibody titers for the differentiation of Lyme neuroborreliosis (LNB) from its mimics. Method This was a retrospective, cross-sectional study conducted at two German neurological centers. Serological parameters (ELISA or CLIA analysis) and clinical presentation of 28 patients with definite LNB were compared to those of 36 patients with neurological symptoms mimicking LNB (mimics). Analysis was performed using receiver operating characteristic (ROC) and binary logistic regression. Results Elevated IgG-titers had a high sensitivity for neuroborreliosis in both centers (0.95 and 1.0). The optimal cutoffvalues were set to 26.35 in center A (ELISA), and 64.0 in center B (CLIA). Diagnostic specificity was 0.41 and 0.89 in this constellation. Elevated IgM-titers showed a high diagnostic specificity for a cutoff at 68.10 (A) and 47.95 (B) (0.93 and 0.89). Sensitivity was 0.45 and 0.5. Overall diagnostic accuracy was low in both centers (A: IgG AUC = 0.665, IgM AUC = 0.629; B: IgG AUC = 0.917, IgM AUC = 0.556). In logistic regression of antibody titers and clinical measures, prediction of LNB was significantly better than the "null hypothesis". Clinical measures showed the highest odds ratio. Conclusion Data show that in addition to the clinical presentation of patients with symptoms suggesting central or peripheral nervous system manifestation, serum IgG-and IgM-titers help to identify LNB-patients. The results should guide physicians counseling patients with suspected LNB about further diagnostic steps and treatment.

show abstract

Section: Discussionsupporting

confidence: 89%

Quantitative serological antibody testing for suspected neuroborreliosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Both ELISA and CLIA could equally detect HBV antigen and antibody titers. However, there is a significant difference in detection sensitivity between the two: CLIA is more sensitive (96.45%) compared to ELISA (77.3%) [37, 38] when serum HBsAg level is low [15].…”

Section: Discussionmentioning

confidence: 99%

A retrospective serological survey of hepatitis B virus infection in Northeast China

Meng

Sui

et al. 2019

BMC Infect Dis

View full text Add to dashboard Cite

Background Hepatitis B virus (HBV) infection is a major public health burden in China although it has steadily declined over the last two decades. A valid updated prevalence of HBV infection in China relies on a large sample size. Hence this study aimed to estimate HBV seroprevalence using a large inpatient population in Northeast China. Methods We consecutively enrolled 218,627 inpatients aged 1–70 years admitted to the First Hospital of Jilin University from January 2010 through December 2014. HBV serological markers were detected by chemiluminescence immunoassay (CLIA). Results Among the 218,627 collected samples, 16,254 (7.43%) were positive for HBsAg and 41.64% of patients were negative for all the HBV markers. The highest HBsAg prevalence was 10.05% in the 41–50 year age group and the lowest were 0.47% in the 1–10 and 2.35% in the 11–20 year age groups, respectively. HBsAg positivity was higher in males compared to females (8.94% vs. 5.80%). An HBsAg positivity of nearly 14% was found in middle-aged males, and positivity was 6.2% in females of childbearing age. One-third of this population only had a single HBsAb marker, which was also detected in 60% of patients aged under 20 years. Conclusion Though universal hepatitis B vaccination of infants has significantly reduced HBsAg prevalence in children, the number of most adults who have been infected with HBV remains steady. Extra care and resources should be provided to HBV-infected middle-aged males to stop the progression of chronic hepatitis B, and HBsAg positive females of childbearing age to block vertical HBV transmission.

show abstract

“…While assessing the SARS-CoV-2 IgG antibody through ELISA initially and by CLIA on follow-up can potentially give rise to confounding factors, current evidence shows that any of these assays can "effectively detect SARS-CoV-2 antibodies." Besides, other studies for hepatitis B surface antigen [14] and Mycoplasma pneumoniae [15] show that while there may be minor discrepancies in quantitative measurements, there is good analytical agreement and high concordance between CLIA and ELISA.…”

Section: Limitations Of the Studymentioning

confidence: 91%

A Prospective Study on Rapidly Declining SARS‐CoV‐2 IgG Antibodies Within One to Three Months of Testing IgG Positive: Can It Lead to Potential Reinfections?

Nag¹,

Chaudhry²,

Mishra³

et al. 2020

Cureus

View full text Add to dashboard Cite

Background COVID-19 immunoglobulin G (IgG) antibodies have been considered to provide protective immunity and its immunoassays have been widely used for serosurveillance. In our serosurveillance on an industrial workforce of randomly selected 3296 subjects, COVID-19 IgG antibody positivity was reported in 7.37% (243) subjects. However, when 30 days later, eight of the 243 COVID-19 IgG antibody-positive individuals complained of symptoms suggestive of COVID-19 infection and were confirmed as COVID-19 infection by reverse transcription-polymerase chain reaction (RT-PCR), their COVID-19 IgG antibodies were retested. Seven of the eight previously IgG positive individuals had lost their protective antibodies. Methods Subsequently, a prospective clinical trial was planned by repeating the test for IgG antibodies on the remaining earlier positive 235 individuals at 45-65 days after their initial test. Only 201 of the 235 individuals consented and participated in the non-randomized single-arm observational trial. Results Only 28.36% (57/201) retained their IgG antibodies and 70.15% (141/201) had lost their IgG antibodies. Three cases reported equivocal results on retesting. Conclusions Our findings show that the protective COVID-19 IgG antibodies rapidly decline over one to three months. Further studies are needed with a quantitative assay over a period with neutralizing antibodies to establish if its decay can potentially lead to reinfections. Rapidly decaying protective IgG antibodies would impact herd immunity and vaccine durability. It is critical for the potential vaccines to generate both protective T-and Bcell immune responses in a sustained manner.

show abstract

Comparing Assay Performance of ELISA and Chemiluminescence Immunoassay in Detecting Antibodies to Hepatitis B Surface Antigen

Cited by 20 publications

References 13 publications

Quantitative serological antibody testing for suspected neuroborreliosis

Quantitative serological antibody testing for suspected neuroborreliosis

A retrospective serological survey of hepatitis B virus infection in Northeast China

A Prospective Study on Rapidly Declining SARS‐CoV‐2 IgG Antibodies Within One to Three Months of Testing IgG Positive: Can It Lead to Potential Reinfections?

Contact Info

Product

Resources

About